1. Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL.
- Author
-
Khouri, I, Sui, D, Jabbour, E, Samuels, B, Turturro, F, Alatrash, G, Anderlini, P, Ahmed, S, Oran, B, Ciurea, S, Marin, D, Olson, A, Patel, K, Popat, U, Ledesma, C, Kadia, T, Ferrajoli, A, Burger, J, Jorgensen, J, Medeiros, L, Bassett, R, and Gulbis, A
- Subjects
Adult ,Aged ,Bendamustine Hydrochloride ,Cyclophosphamide ,Disease-Free Survival ,Female ,Humans ,Leukemia ,Lymphocytic ,Chronic ,B-Cell ,Male ,Middle Aged ,Rituximab ,Survival Rate ,Transplantation Conditioning ,Vidarabine - Abstract
Bendamustine has shown a favorable safety profile when included in chemotherapy regimens for several types of lymphoma, including CLL. This study investigated the long-term effect of adding bendamustine to a conditioning regimen on survival, rate of engraftment, immune recovery and GvHD after allogeneic stem cell transplantation (alloSCT) in CLL patients. These outcomes were compared with the fludarabine, cyclophosphamide and rituximab (FCR) conditioning regimen. We reviewed the data for 89 CLL patients treated on three trials at our institution. Twenty-six (29%) patients received bendamustine, fludarabine and rituximab (BFR) and 63 (71%) received FCR. Patient characteristics were similar in both groups. Ten (38%) BFR-treated patients vs only two (3%) FCR-treated patients did not experience severe neutropenia (P=
- Published
- 2017